Takeda settles diabetes drug patent suits with 11 generic firms

Bs_logoImage
BS Reporter Mumbai
Last Updated : Jan 20 2013 | 1:37 AM IST

Japan’s Takeda Pharmaceutical Company has settled patent infringement suits out of court with 11 generic drug companies, including Ranbaxy Laboratories, Torrent Pharmaceuticals, Dr Reddy’s Laboratories, Wockhardt and Aurobindo Pharma, over its flagship diabetes drug Actos and its variants.

The settlement will help Ranbaxy, along with Mylan and Watson, launch generic versions of the drug on August 17, 2012 or earlier under certain circumstances. These three companies are the first to challenge the patent of this drug with paragraph IV marketing applications in the US, which will help to gain 180-day marketing exclusivity during the launch.

Takeda has also granted Israeli drug company Teva a licence to market an authorised generic version of the drug in the US during the same period. Rest of the generic companies, including Dr Reddy’s, Torrent, Wockhardt and Aurobindo Pharma, can launch their versions after the 180-day exclusive period.

According to data of drug sales tracking agency IMS, Actos and its variants had sales of $4 billion last year. Takeda is the inventor and developer of Actos, which was launched commercially in the US in 1999 for the treatment of type 2 diabetes and has been prescribed for more than 10 million patients to date.

Takeda had filed the lawsuits against these companies to enforce several patents that expire in 2016 relating to Actos, Actoplus met, and Duetact. Actos (pioglitazone HCl), Actoplus met (pioglitazone HCl and metformin HCl), Actoplus met XR (pioglitazone HCl and extended-release metformin HCl), and Duetact (pioglitazone HCl and glimepiride) are prescription medications to improve blood sugar (glucose) control in adults with type 2 diabetes.

Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 24 2010 | 1:22 AM IST